Global Clonorchiasis Market Size, Share, Forecast Report, 2020-2027

Clonorchiasis is infection with the liver fluke Clonorchis sinensis caused due to eating undercooked freshwater fish. Fever, chills, epigastric pain, tender hepatomegaly, diarrhea, and mild jaundice are the major symptoms of the diseases. Different types of diagnostic tests are used to diagnose the disease in the patients. Clonorchiasis is a problem in Israel, and the incidence rate is increasing continuously in Europe and Asia Pacific countries. Increasing prevalence of clonorchiasis, poor diet, increasing geriatric population and changing lifestyle have driven the growth of the market. During last two decades, there has been a significant increase in the number of the patient suffering from the clonorchiasis. The patient having gastrointestinal diseases are more likely to suffer from this disease. According to the National Institutes of Health, in 2014, 70 to 80 million people affected by all digestive diseases. Moreover, increasing healthcare expenditure, government support for research & development, and increasing prevalence of gastrointestinal diseases have fuelled the growth of the market. Increasing awareness about health hygiene has also contributed to the growth of the market. However, the high cost of the tests & the treatment may lead to slow the growth of the market.

The global clonorchiasis market is expected to grow at a CAGR of 5.4 % during forecast period.
Segmentation

The global clonorchiasis market is segmented on the basis of parasites, therapy, and end users.

On the basis of parasites, the market is segmented into Clonorchis sinensis, Opisthorchis viverrini, Opisthorchis felineus, and others.

On the basis of therapy, the market is segmented into diagnosis and treatment. Diagnosis is further segmented into the microscopic examination, X-ray, serologic tests, and others. Treatment is sub-segmented into praziquantel, cool, cystic, biltricide, and others.

On the basis of end users, the market is segmented into hospital, clinics, and others.
Key Players for Global Clonorchiasis Market

The key players in the global clonorchiasis market are Pfizer (U.S), Bayer AG (Germany), Provet (Switzerland), Virbac (India), Cipla (India), Novartis AG (Switzerland), CIRON Drugs & Pharmaceuticals Pvt. Ltd. (India), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (U.S.), Arsanis, Inc. (Austria), Novabiotics (U.K.), GlaxoSmithKline plc. (U.K.), Teva Pharmaceutical Industries Ltd (Taiwan)